[{"NetIncomeLoss_1_Q3_USD":-158991.0,"AssetsCurrent_0_Q3_USD":1434591.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_1_Q3_USD":0.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_2_Q3_USD":0.0,"NetCashProvidedByUsedInInvestingActivities_2_Q3_USD":-149500000.0,"AccruedLiabilitiesCurrent_0_Q3_USD":102573.0,"CommitmentsAndContingencies_0_Q3_USD":null,"GeneralAndAdministrativeExpense_1_Q3_USD":174671.0,"GeneralAndAdministrativeExpense_2_Q3_USD":186388.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"ProceedsFromRelatedPartyDebt_2_Q3_USD":136590.0,"GainLossOnInvestments_1_Q3_USD":15680.0,"GainLossOnInvestments_2_Q3_USD":15680.0,"Liabilities_0_Q3_USD":5361160.0,"Cash_0_Q3_USD":1064954.0,"IncreaseDecreaseInAccountsPayable_2_Q3_USD":6087.0,"PaymentsOfStockIssuanceCosts_2_Q3_USD":3375988.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_1_Q3_USD":0.0,"FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_2_Q3_USD":0.0,"FairValueAssetsLevel2ToLevel1TransfersAmount_0_Q3_USD":0.0,"NetCashProvidedByUsedInFinancingActivities_2_Q3_USD":151050602.0,"ProceedsFromIssuanceOfPrivatePlacement_2_Q3_USD":4990000.0,"AssetsHeldInTrustNoncurrent_0_Q3_USD":149515680.0,"UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_0_Q3_USD":0.0,"IncreaseDecreaseInPrepaidExpensesOther_2_Q3_USD":369637.0,"TemporaryEquityCarryingAmountAttributableToParent_0_Q3_USD":140589110.0,"RepaymentsOfRelatedPartyDebt_2_Q3_USD":200000.0,"DueToRelatedPartiesCurrent_0_Q3_USD":20000.0,"NetIncomeLoss_2_Q3_USD":-170708.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"CashEquivalentsAtCarryingValue_0_Q3_USD":0.0,"AdditionalPaidInCapital_0_Q3_USD":5170196.0,"RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_2_Q3_USD":11717.0,"AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_1_Q3_USD":8755181.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":1064954.0,"AccountsPayableCurrent_0_Q3_USD":6087.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_Q3_USD":1064954.0,"LiabilitiesCurrent_0_Q3_USD":128660.0,"NetAssetValuePerShare_0_Q3_USD":1.0,"IncreaseDecreaseInAccruedLiabilities_2_Q3_USD":32573.0,"NetCashProvidedByUsedInOperatingActivities_2_Q3_USD":-485648.0,"StockholdersEquity_0_Q3_USD":5000001.0,"PreferredStockSharesAuthorized_0_Q3_shares":1000000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":150950271.0,"PreferredStockValue_0_Q3_USD":0.0,"ProceedsFromIssuanceInitialPublicOffering_2_Q3_USD":149500000.0,"OperatingIncomeLoss_1_Q3_USD":-174671.0,"OperatingIncomeLoss_2_Q3_USD":-186388.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q3_USD":0.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"Assets_0_Q3_USD":150950271.0,"UnrecognizedTaxBenefits_0_Q3_USD":0.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-170708.0,"PrepaidExpenseCurrent_0_Q3_USD":369637.0,"Ticker":"NAUT","CIK":"1808805","name":"ARYA SCIENCES ACQUISITION CORP III","OfficialName":"Nautilus Biotechnolgy Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"491482396.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201113"}]